Dengue and Zika Viruses: Epidemiological History, Potential Therapies, and Promising Vaccines

Dengue virus (DENV), which can lead to fatal hemorrhagic fever, affects 390 million people worldwide. The closely related Zika virus (ZIKV) causes microcephaly in newborns and Guillain-Barré syndrome in adults. Both viruses are mostly transmitted by <i>Aedes albopictus</i> and <i>A...

Full description

Bibliographic Details
Main Authors: Nelly M. Silva, Nuno C. Santos, Ivo C. Martins
Format: Article
Language:English
Published: MDPI AG 2020-09-01
Series:Tropical Medicine and Infectious Disease
Subjects:
Online Access:https://www.mdpi.com/2414-6366/5/4/150
_version_ 1797552795918794752
author Nelly M. Silva
Nuno C. Santos
Ivo C. Martins
author_facet Nelly M. Silva
Nuno C. Santos
Ivo C. Martins
author_sort Nelly M. Silva
collection DOAJ
description Dengue virus (DENV), which can lead to fatal hemorrhagic fever, affects 390 million people worldwide. The closely related Zika virus (ZIKV) causes microcephaly in newborns and Guillain-Barré syndrome in adults. Both viruses are mostly transmitted by <i>Aedes albopictus</i> and <i>Aedes aegypti</i> mosquitoes, which, due to globalization of trade and travel alongside climate change, are spreading worldwide, paving the way to DENV and ZIKV transmission and the occurrence of new epidemics. Local outbreaks have already occurred in temperate climates, even in Europe. As there are no specific treatments, these viruses are an international public health concern. Here, we analyze and discuss DENV and ZIKV outbreaks history, clinical and pathogenesis features, and modes of transmission, supplementing with information on advances on potential therapies and restraining measures. Taking advantage of the knowledge of the structure and biological function of the capsid (C) protein, a relatively conserved protein among flaviviruses, within a genus that includes DENV and ZIKV, we designed and patented a new drug lead, pep14-23 (WO2008/028939A1). It was demonstrated that it inhibits the interaction of DENV C protein with the host lipid system, a process essential for viral replication. Such an approach can be used to develop new therapies for related viruses, such as ZIKV.
first_indexed 2024-03-10T16:06:08Z
format Article
id doaj.art-ed4eb85f7d914a938443447b5869f364
institution Directory Open Access Journal
issn 2414-6366
language English
last_indexed 2024-03-10T16:06:08Z
publishDate 2020-09-01
publisher MDPI AG
record_format Article
series Tropical Medicine and Infectious Disease
spelling doaj.art-ed4eb85f7d914a938443447b5869f3642023-11-20T14:52:47ZengMDPI AGTropical Medicine and Infectious Disease2414-63662020-09-015415010.3390/tropicalmed5040150Dengue and Zika Viruses: Epidemiological History, Potential Therapies, and Promising VaccinesNelly M. Silva0Nuno C. Santos1Ivo C. Martins2Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisbon, PortugalInstituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisbon, PortugalInstituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisbon, PortugalDengue virus (DENV), which can lead to fatal hemorrhagic fever, affects 390 million people worldwide. The closely related Zika virus (ZIKV) causes microcephaly in newborns and Guillain-Barré syndrome in adults. Both viruses are mostly transmitted by <i>Aedes albopictus</i> and <i>Aedes aegypti</i> mosquitoes, which, due to globalization of trade and travel alongside climate change, are spreading worldwide, paving the way to DENV and ZIKV transmission and the occurrence of new epidemics. Local outbreaks have already occurred in temperate climates, even in Europe. As there are no specific treatments, these viruses are an international public health concern. Here, we analyze and discuss DENV and ZIKV outbreaks history, clinical and pathogenesis features, and modes of transmission, supplementing with information on advances on potential therapies and restraining measures. Taking advantage of the knowledge of the structure and biological function of the capsid (C) protein, a relatively conserved protein among flaviviruses, within a genus that includes DENV and ZIKV, we designed and patented a new drug lead, pep14-23 (WO2008/028939A1). It was demonstrated that it inhibits the interaction of DENV C protein with the host lipid system, a process essential for viral replication. Such an approach can be used to develop new therapies for related viruses, such as ZIKV.https://www.mdpi.com/2414-6366/5/4/150dengueZika<i>Flavivirus</i>epidemiology<i>Aedes</i>
spellingShingle Nelly M. Silva
Nuno C. Santos
Ivo C. Martins
Dengue and Zika Viruses: Epidemiological History, Potential Therapies, and Promising Vaccines
Tropical Medicine and Infectious Disease
dengue
Zika
<i>Flavivirus</i>
epidemiology
<i>Aedes</i>
title Dengue and Zika Viruses: Epidemiological History, Potential Therapies, and Promising Vaccines
title_full Dengue and Zika Viruses: Epidemiological History, Potential Therapies, and Promising Vaccines
title_fullStr Dengue and Zika Viruses: Epidemiological History, Potential Therapies, and Promising Vaccines
title_full_unstemmed Dengue and Zika Viruses: Epidemiological History, Potential Therapies, and Promising Vaccines
title_short Dengue and Zika Viruses: Epidemiological History, Potential Therapies, and Promising Vaccines
title_sort dengue and zika viruses epidemiological history potential therapies and promising vaccines
topic dengue
Zika
<i>Flavivirus</i>
epidemiology
<i>Aedes</i>
url https://www.mdpi.com/2414-6366/5/4/150
work_keys_str_mv AT nellymsilva dengueandzikavirusesepidemiologicalhistorypotentialtherapiesandpromisingvaccines
AT nunocsantos dengueandzikavirusesepidemiologicalhistorypotentialtherapiesandpromisingvaccines
AT ivocmartins dengueandzikavirusesepidemiologicalhistorypotentialtherapiesandpromisingvaccines